RenovoRx IncNASDAQ:RNXT
- LAST PRICE1.0400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.9800/ 102
- Ask / Lots1.0700/ 1
- Open / Previous Close--- / 1.0400
- Day Range---
- 52 Week Range
- Volume35
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RNXT |
|---|---|---|
| 10:13 ET | 100 | 1.0199 |
| 12:39 ET | 100 | 0.98 |
| 01:40 ET | 2000 | 1.019 |
| 02:12 ET | 200 | 1.02 |
| 02:27 ET | 6800 | 1.02 |
| 02:30 ET | 134 | 0.9818 |
| 02:43 ET | 1688 | 1.02 |
| 03:51 ET | 100 | 1.04 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
RenovoRx Inc | 24.9M | -1.7x | --- |
Athira Pharma Inc | 24.6M | -0.2x | --- |
Lisata Therapeutics Inc | 24.2M | -1.1x | --- |
Neurosense Therapeutics Ltd | 23.9M | -2.8x | --- |
Onconetix Inc | 24.1M | 0.0x | --- |
Tempest Therapeutics Inc | 23.7M | -0.6x | --- |
Company Information
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Contact Information
- Headquarters
- 333 W Santa Clara St Ste 900SAN JOSE, CA, United States 95113-1716
- Phone
- 408-800-2649
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Co-Founder, Chief Medical Officer
- Ramtin Agah
- Chief Executive Officer, Director
- Shaun Bagai
- Principal Financial Officer and Accounting Officer, Vice President, Controller
- Ronald Kocak
- Chief Clinical Officer
- Leesa Gentry
- Lead Independent Director
- David Diamond
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 24.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.61 |
Book Value | $-0.28 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
